Stem Cell Clinic

Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation &…

By Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced new positive Phase 1 data on briquilimab (formerly known as JSP191) in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The data are being featured in two oral presentations and one poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (February 15-19, 2023; Orlando, Florida).

Read more here:
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation &...

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia…

By Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that new follow-up data from Jasper’s investigator-sponsored study of briquilimab (formerly known as JSP191) as a conditioning agent in the treatment of Fanconi Anemia (FA) were presented in a poster presentation today at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR taking place in Orlando, Florida.

Here is the original post:
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia...

Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

By Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of healthcare industry veteran Vishal Kapoor, Partner of Avego Management, to Jasper’s Board of Directors.

Continued here:
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To…

By Global News Feed

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced it will participate in an event hosted by Solve M.E. Diagnostics and The Biotechnology Innovation Organization (BIO) titled, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?,” being held virtually on Tuesday, February 21, 2023, from 10:00 AM – 1:00 PM PT.

See the original post:
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To...

Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN…

By Global News Feed

The NEW Amarin and NEW Board is On the Right Track – Leading Independent Experts, ISS and Glass Lewis, Agree that Sarissa Representation is Not Warranted

See the original post:
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN...

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

By Global News Feed

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the “Dividend Stock”).

Original post:
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units (RSUs) of Sutro common stock. These grants were made as an inducement material to the employees’ acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

View original post here:
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

→←